Abstract: The present invention is directed to a method for determining a paroxysmal slow waves event (PSWE) so as to determine blood-brain barrier dysfunction (BBBD) or increased risk of developing a neurological disease or disorder in a subject.

Abstract: A combination therapy, comprising a pharmaceutical composition of an N-Methyl D-Aspartate receptor (NMDA) receptor blocker and a Transforming Growth Factor beta (TGF-?) receptor antagonist, for treatment of brain diseases associated with BBB dysfunction.

Abstract: Transcranial magnetic stimulation (TMS) is used to modulate permeability of the blood brain barrier in a transient, safe and non-invasive manner. A conventional or deep TMS coil may be placed on a head in a vicinity of a tumor, for example. A series of magnetic pulses is provided to the brain with a tailored stimulation protocol. In one of many possible clinical applications, a pharmaceutical substance may be introduced during a time frame before, during or after providing the magnetic pulses to treat a tumor in the brain.

Abstract: The present invention provides methods of treating epilepsy and other neurological disorders.

Abstract: The present invention provides methods of treating epilepsy and other neurological disorders. The methods generally involve administering to an individual in need thereof an effective amount of an agent that blocks a transforming growth factor-beta pathway.

Abstract: Transcranial magnetic stimulation (TMS) is used to modulate permeability of the blood brain barrier in a transient, safe and non-invasive manner. A conventional or deep TMS coil may be placed on a head in a vicinity of a tumor, for example. A series of magnetic pulses is provided to the brain with a tailored stimulation protocol. In one of many possible clinical applications, a pharmaceutical substance may be introduced during a time frame before, during or after providing the magnetic pulses to treat a tumor in the brain.

Abstract: Transcranial magnetic stimulation (TMS) is used to modulate permeability of the blood brain barrier in a transient, safe and non-invasive manner. A conventional or deep TMS coil may be placed on a head in a vicinity of a tumor, for example. A series of magnetic pulses is provided to the brain with a tailored stimulation protocol. In one of many possible clinical applications, a pharmaceutical substance may be introduced during a time frame before, during or after providing the magnetic pulses to treat a tumor in the brain.

Abstract: Provided are compositions which include N-methyl-d-aspartate receptor (NMDA-R) antagonists. Moreover, provided are methods for reducing the permeability of the blood-brain-barrier, in a patient, by administering to the patient, a composition which includes N-methyl-d-aspartate receptor (NMDA-R) antagonists.

Abstract: Transcranial magnetic stimulation (TMS) is used to modulate permeability of the blood brain barrier in a transient, safe and non-invasive manner. A conventional or deep TMS coil may be placed on a head in a vicinity of a tumor, for example. A series of magnetic pulses is provided to the brain with a tailored stimulation protocol. In one of many possible clinical applications, a pharmaceutical substance may be introduced during a time frame before, during or after providing the magnetic pulses to treat a tumor in the brain.

Abstract: Transcranial magnetic stimulation (TMS) is used to modulate permeability of the blood brain barrier in a transient, safe and non-invasive manner. A conventional or deep TMS coil may be placed on a head in a vicinity of a tumor, for example. A series of magnetic pulses is provided to the brain with a tailored stimulation protocol. In one of many possible clinical applications, a pharmaceutical substance may be introduced during a time frame before, during or after providing the magnetic pulses to treat a tumor in the brain.

Abstract: The present invention provides methods of treating epilepsy and other neurological disorders.

Abstract: The present invention provides methods of treating epilepsy and other neurological disorders. The methods generally involve administering to an individual in need thereof an effective amount of an agent that blocks a transforming growth factor-beta pathway.

Abstract: A method of analyzing a stream of imaging data is disclosed. The method comprises: for each picture-element of the data, associating a vector of features indicative of temporal intensity variation relative to baseline intensity, thereby providing a plurality of vectors. The method further comprises clustering the picture-elements according to the vectors, thereby providing a plurality of clusters, and identifying different compartments in the vasculature based on the clusters.

Abstract: A method of analyzing a stream of imaging data is disclosed. The method comprises: for each picture-element of the data, associating a vector of features indicative of temporal intensity variation relative to baseline intensity, thereby providing a plurality of vectors. The method further comprises clustering the picture-elements according to the vectors, thereby providing a plurality of clusters, and identifying different compartments in the vasculature based on the clusters.

Abstract: The present invention provides methods of treating epilepsy and other neurological disorders. The methods generally involve administering to an individual in need thereof an effective amount of an agent that blocks a transforming growth factor-beta pathway.

Abstract: Specific PON1 and ACHE alleles segregate in linkage, forming an haplotype which directly correlates with higher susceptibility to develop Parkinson's Disease (PD). This PD-susceptibility haplotype is herein presented as a tool for predicting the risk of developing Parkinson's Disease and its severity, both for an individual and for the population in general. Thus, the present invention provides the use of said PD-susceptibility haplotype in diagnostic and screening methods.

Abstract: The invention relates to antibodies recognizing acetylcholinesterase or a C-terminal peptide derived from acetyl-cholinesterase, useful in diagnosing central nervous system (CNS) stress, elevated glucocorticoid level, disruption of the blood-brain barrier or Alzheimer's disease. The invention also relates to methods for the diagnosis of central nervous system (CNS) stress, elevated glucocorticoid level or disruption of the blood-brain barrier in a mammal, by use of the antibodies of the invention.

Abstract: The invention relates to antibodies recognizing acetylcholinesterase or a C-terminal peptide derived from acetyl-cholinesterase, useful in diagnosing central nervous system (CNS) stress, elevated glucocorticoid level, disruption of the blood-brain barrier or Alzheimer's disease. The invention also relates to methods for the diagnosis of central nervous system (CNS) stress, elevated glucocorticoid level or disruption of the blood-brain barrier in a mammal, by use of the antibodies of the invention.

Abstract: A pharmaceutical composition for facilitating passage of compounds through the blood-brain barrier comprising the agent ACHE-I4 readthrough (SEQ ID No:1) splice variant or the I4 peptide (SEQ ID No:2) and analogues of each thereof and a pharmaceutically acceptable carrier is disclosed. Alternatively, the pharmaceutical composition for facilitating passage of compounds through the blood-brain barrier can comprise the agents adrenaline, atropine, dopamine and/or an adrenergic combination and a pharmaceutically acceptable carrier. The composition can comprise at least two of the agents. The composition of the present invention can optionally include the compound to be transported across the blood-brain barrier. Alternatively, the compound can be co-administered (simultaneously) with the composition or can be administered at some point during the biologically effective period of the action of the composition.

Abstract: A synthetic nuclease resistant antisense oligodeoxynucleotide (AS-ODN) capable of selectively modulating human acetylcholinesterase (AChE) production and a composition comprising at least one AS-ODN as an active ingredient. A nuclease resistant antisense targeted against the splice junction in the AChE mRNA post-splice message is disclosed. The synthetic nuclease resistant AS-ODNs are capable of selectively modulating human AChE production in the central nervous system or capable of selectively reducing human AChE deposition of the neuromuscular junction. The present invention also provides a method to restore balanced cholinergic signalling in the brain and spinal cord or reduce AChE in the neuromuscular junction in patients in need of such treatment by administering to a patient in need of such treatment a therapeutically effective amount of at least one of the synthetic nuclease resistant AS-ODN capable of selectively modulating human AChE production.